Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177472 | 0.81 | DYRK1A (0.44) | DYRK1ASCN5AOGATGFBR1PCSK9 | |
| SCHEMBL3347519 | 0.75 | GRM4 (0.46) | DYRK1A | |
| SCHEMBL3347027 | 0.74 | GRM5 (0.50) | DYRK1ATGFBR1 | |
| SCHEMBL3347789 | 0.74 | GRM5 (0.49) | DYRK1ASCN5AOGATGFBR1PIK3CD | |
| SCHEMBL3346766 | 0.73 | GRM5 (0.53) | TGFBR1 | |
| SCHEMBL3346205 | 0.73 | OGA (0.53) | DYRK1ASCN5AOGATGFBR1PCSK9 | |
| SCHEMBL3346384 | 0.72 | GRM5 (0.43) | DYRK1AOGATGFBR1 | |
| SCHEMBL3345883 | 0.72 | DYRK1A (0.37) | DYRK1ASCN5AOGATGFBR1 | |
| SCHEMBL3347627 | 0.72 | OGA (0.38) | DYRK1ASCN5AOGATGFBR1PCSK9 | |
| SCHEMBL3346885 | 0.72 | OGA (0.38) | DYRK1ASCN5AOGATGFBR1PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2920171-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9730940-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150353552-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC | 2015-12-10 | — | — | US | disclosed |
| EP-2920171-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014075392-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353552-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | DYRK1A 3498/4885SCN5A 3081/4885OGA 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.